PipelineReview.com9h
Akeso’s Gumokimab Monoclonal Antibody (IL-17) New Drug Application for the Treatment of Moderate to Severe Psoriasis Accepted by NMPA
HONG KONG, China I January 26, 2025 I Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that the New Drug Application (NDA) of its ...
PipelineReview.com9h
Pfizer’s BRAFTOVI® Combination Regimen Demonstrates Improved Response in Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer
NEW YORK, NY, USA I5, 2025 I Pfizer Inc. (NYSE: PFE) today announced positive results from the Phase 3 BREAKWATER trial evaluating BRAFTOVI® ...
PipelineReview.com9h
AB2 Bio signs U.S. option and licensing agreement with Nippon Shinyaku for Tadekinig alfa for an ultra-rare autoimmune disease
LAUSANNE, Switzerland I7, 2025 I AB2 Bio Ltd., a biotechnology company developing innovative therapies for the treatment of severe systemic ...
PipelineReview.com3d
Novo Nordisk successfully completes phase 1b/2a trial with subcutaneous amycretin in people with overweight or obesity
BAGSVAERD, Denmark I January 24, 2025 I Novo Nordisk today announced topline results from a phase 1b/2a clinical trial with amycretin, a unimolecular GLP-1 and amylin receptor agonist intended for ...
PipelineReview.com3d
EXUMA Biotech Announces Phase 1 Results for its Autologous HER2 Directed, Tumor Metabolism Regulated (TMR) CAR-T Product at ASCO GI 2025
EXUMA now advancing its clinically de-risked solid tumor & hematologic CARs with in vivo GCAR ™ platform and SCL mRNA technology WEST PALM BEACH, FL, USA I January 23, 2025 I EXUMA Biotech, Corp., a ...
PipelineReview.com3d
Antennova Presents Latest Phase I/II Data on ATN-022 in Advanced/Metastatic Gastric Cancer, Including an ORR of 42.9%, at ASCO GI 2025
BOSTON, MA, USA I1, 2025 I Antennova, a clinical-stage biotech company focused on oncology today announced the presentation of latest data from ...
PipelineReview.com3d
Strategic Collaboration with Novo Nordisk to Develop Oral Therapies for Sickle Cell Disease and Other Chronic Diseases
DURHAM, NC, USA I January 22, 2025 I IMMvention Therapeutix, Inc., an early-stage biotechnology company focused on discovering and developing human therapeutics, today announced a strategic ...
PipelineReview.com3d
āshibio Doses First Patient in ANDECAL study, a Phase 2/3 Trial of Andecaliximab for Treatment of Fibrodysplasia Ossificans Progressiva (FOP)
BRISBANE, CA, USA I January 23, 2025 I āshibio, a privately held, clinical-stage biotechnology company developing novel therapeutics for the treatment of severe bone and connective tissue disorders, ...
PipelineReview.com3d
Aro Biotherapeutics Doses First Patient in Phase 1b Trial of ABX1100 in Late-Onset Pompe Disease (LOPD)
Trial aims to establish safety and provide proof of concept for GYS1 inhibition as promising new treatment strategy in patients with late-onset Pompe disease Dosing milestone extends momentum of ...
PipelineReview.com3d
Ymmunobio and PSI Secure Innosuisse Grant to Advance Radio-pharmaceutical YB-800
PRINCETON, NJ, USA I January 23, 2025 I Ymmunobio (YB) is excited to share that they in collaboration with the Paul Scherrer Institute (PSI) have received Innosuisse support to develop innovative ...